Avoiding Late Diagnosis of Ovarian Cancer (ALDO)

niversity College London0 sites875 target enrollmentFebruary 17, 2020

Overview

2022 Results article in http://dx.doi.org/10.1136/jmg-2022-108741 (added 18/08/2023)

Registry

who.int

Start Date

February 17, 2020

End Date

June 30, 2022

Last Updated

2 years ago

Study Type

Interventional

Sex

Female

Sponsor

niversity College London

•1\. Women who have tested postive for a pathogenic BRCA1 or BRCA2 mutation
•2\. Women aged 35 years or over
•3\. Women who still have at least one ovary or fallopian tube in situ
•4\. Women who are able and willing to travel to one of the named referral centres

•1\. Women who have tested negative for pathogenic BRCA1 or BRCA2 gene mutation
•2\. Women who have not been tested for a pathogenic BRCA1 or BRCA2 gene mutation
•3\. Women who are less than 35 years of age
•4\. Women who are pregnant are not eligible for the ROCA® Test until 6 weeks after the end of their pregnancy. Neither CA125 nor ultrasound scanning can be used reliably to screen for OC during pregnancy
•5\. Women with a past history of bilateral salpingo\-oophorectomy (Note: Women who still have one or more fallopian tube or ovary in situ are still eligible as they remain at increased risk of ovarian/tubal cancer)
•6\. Women previously treated for an ovarian malignancy
•7\. Women who are under investigation for suspected OC
•8\. Women currently being treated or within 6 weeks of treatment for any other malignancy